Bio-Techne (TECH)
NASDAQ:TECH
Want to see TECH full AI Analyst Report?
TECH Stock Chart & Stats
$59.23
-$0.13(-0.17%)
At close: 4:00 PM EST
$59.23
-$0.13(-0.17%)
Day’s Range― - ―
52-Week Range$43.20 - $72.16
Previous CloseN/A
Volume102.39K
Average Volume (3M)3.29M
Market Cap
$8.22B
Enterprise Value$8.17B
Total Cash (Recent Filing)$209.82M
Total Debt (Recent Filing)$290.32M
Price to Earnings (P/E)74.7
Beta0.94
Next Earnings
Aug 11, 2026EPS Estimate
0.52Next Dividend Ex-DateN/A
Dividend Yield0.54%
Share Statistics
EPS (TTM)0.71
Shares Outstanding156,568,760
10 Day Avg. Volume2,979,678
30 Day Avg. Volume3,291,370
Financial Highlights & Ratios
PEG Ratio-1.97
Price to Book (P/B)4.22
Price to Sales (P/S)6.64
P/FCF Ratio31.59
Enterprise Value/Market Cap0.99
Enterprise Value/Revenue6.75
Enterprise Value/Gross Profit10.39
Enterprise Value/Ebitda31.55
Forecast
1Y Price Target
$59.89Price Target Upside1.11% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering11
EPS Forecast (FY)1.93
Revenue Forecast (FY)$1.21B
Bulls Say, Bears Say
Bulls Say
Strong Cash Generation & Conservative Balance SheetHigh-quality operating cash flow that exceeds operating profit, strong free cash flow conversion, and very low leverage give durable financial flexibility. This supports R&D, instrument placements, consumable commercialization and M&A or buybacks through cyclical demand troughs, reducing financing risk.
Spatial Biology & COMET Platform MomentumRapid COMET growth and a record backlog indicate a scalable, high-value instrument franchise. Platform adoption drives recurring consumables and services revenue, higher customer lock-in, and expanded clinical/commercial use cases, supporting sustainable higher-margin growth over multiple years.
Stable Demand From Large Pharma And China ExpansionConsistent large-pharma strength and steady China growth diversify revenue away from volatile early-stage biotech. Long-term pharma programs and increasing demand from Chinese biopharma/CROs for ADCs and cell therapy create durable, repeatable demand and reduce sensitivity to small-biotech funding cycles.
Bears Say
Material Recent Revenue DeclineA nearly 40% TTM revenue drop reflects pronounced demand reset and/or lumpy prior-year comparables. Such a step-change impairs operating leverage, limits reinvestment capacity, and means multi-quarter recovery is required before topline-driven margin and EPS improvement can be sustained.
Compressed Margins And Adverse Mix DynamicsSignificant year-over-year margin compression indicates mix shifts toward lower-margin products and volume shortfalls. Restoring prior profitability will require sustained growth in higher-margin instruments/consumables or structural cost improvements, which can take several quarters and depends on durable demand recovery.
Emerging-biotech Weakness And Order Timing VolatilityDependence on large, lumpy orders and early-stage biotech spend creates unpredictable revenue timing. Fast-track customer timing and OEM shipment variability can cause quarter-to-quarter volatility, delaying consumable pull-through and complicating forecasting and capacity planning over several quarters.
Bio-Techne News
TECH FAQ
What was Bio-Techne’s price range in the past 12 months?
Bio-Techne lowest stock price was $43.20 and its highest was $72.16 in the past 12 months.
What is Bio-Techne’s market cap?
Bio-Techne’s market cap is $8.22B.
When is Bio-Techne’s upcoming earnings report date?
Bio-Techne’s upcoming earnings report date is Aug 11, 2026 which is in 61 days.
How were Bio-Techne’s earnings last quarter?
Bio-Techne released its earnings results on May 06, 2026. The company reported $0.53 earnings per share for the quarter, missing the consensus estimate of $0.534 by -$0.004.
Is Bio-Techne overvalued?
According to Wall Street analysts Bio-Techne’s price is currently Undervalued.
Does Bio-Techne pay dividends?
Bio-Techne pays a Quarterly dividend of $0.08 which represents an annual dividend yield of 0.54%. See more information on Bio-Techne dividends here
What is Bio-Techne’s EPS estimate?
Bio-Techne’s EPS estimate is 0.52.
How many shares outstanding does Bio-Techne have?
Bio-Techne has 156,568,760 shares outstanding.
What happened to Bio-Techne’s price movement after its last earnings report?
Bio-Techne reported an EPS of $0.53 in its last earnings report, missing expectations of $0.534. Following the earnings report the stock price went down -16.364%.
Which hedge fund is a major shareholder of Bio-Techne?
Currently, no hedge funds are holding shares in TECH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Bio-Techne Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$59.89 (1.11% Upside)
$59.89 (1.11% Upside)
Blogger Sentiment
Bullish
TECH Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 327.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $320.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 1.5%
Last 30 Days ▲ 0.7%
Last 30 Days ▲ 0.7%
News Sentiment
Very Bearish
Bullish news 19%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
2.75%
12-Months-Change
Fundamentals
Return on Equity
5.49%
Trailing 12-Months
Asset Growth
-3.54%
Trailing 12-Months
Company Description
Bio-Techne
Bio-Techne Corporation, headquartered in Minneapolis, Minnesota, is a global enterprise specializing in the development, production, and distribution of specialized life science tools, instrumentation, and support solutions for both research and clinical diagnostic markets. The company is organized into two key business units: Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment manufactures a broad array of biological components, including cytokines, growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies, which are instrumental across life science research, diagnostic applications, and advancements in cell and gene therapy. This division further provides sophisticated proteomic analysis platforms, encompassing automated western blot and multiplexed ELISA workflows, coupled with relevant instrumentation and immunoassay kits designed for precise protein quantification in various biological fluids. The Diagnostics and Genomics segment is dedicated to developing and manufacturing diagnostic offerings, such as controls, calibrators, and specific diagnostic assays tailored for regulated markets. Its portfolio extends to innovative exosome-based molecular diagnostic tests, advanced in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and a variety of genetic and oncology kits for both research and clinical use. Additionally, this segment supplies products vital for genetic carrier screening, oncology diagnostics, molecular controls, and general research, alongside instrumentation and process controls for hematology, blood chemistry, gas analysis, and coagulation diagnostic applications. Its comprehensive product suite is offered under prominent brands including R&D Systems, Tocris Biosciences, Novus Biologicals, ProteinSimple, Advanced Cell Diagnostics, Exosome Diagnostics, and Asuragen. Founded in 1976 as Techne Corporation, the company adopted its current name, Bio-Techne Corporation, in November 2014.
TECH Earnings Call
Q3 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlighted strong execution in high-value growth vectors (Spatial Biology/COMET, GMP proteins excl. timing impacts, Proteomic Analysis instruments, large pharma strength and four consecutive quarters of China growth), solid sequential margin improvement and robust cash generation. Offsetting these positives were a 2% organic revenue decline, continued weakness in emerging/early-stage biotech spending, timing headwinds from two fast-track cell therapy customers and an OEM order, and YoY mix-related margin pressure. Management expects near-term organic revenue to be roughly flat but positions the business for an inflection in fiscal 2027 as funding improvements translate to customer spending.View all TECH earnings summariesTECH Net revenue Breakdown
71.35% Protein Sciences
28.39% Diagnostics and Genomics
-0.08% Intersegment
0.34% Other revenue
TECH Stock 12 Month Forecast
Average Price Target
$59.89
▲(1.11% Upside)
Technical Analysis
Corcept Therapeutics
―
Halozyme
―
Jazz Pharmaceuticals
―
Rhythm Pharmaceuticals
―
Roivant Sciences
―
Ownership Overview
0.30% Insiders
41.71% Mutual Funds
21.62% Other Institutional Investors
9.54% Public Companies and
Individual Investors